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Abstract 19
The ability of dairy Debaryomyces hansenii, Kluyveromyces lactis and 20
Kluyveromyces marxianus strains to release the casein-derived 21
antihypertensive sequences RYLGY, AYFYPEL, LHLPLP, HLPLP, VPP and/or 22
IPP was examined. Yeast strains were grown in medium with casein as sole 23
nitrogen source and the yeast casein hydrolysates (CSHs) were analysed by 24
HPLC-MS/MS to search for the six antihypertensive sequences. Only LHLPLP 25
and HLPLP were identified in CSHs and exclusively in D. hansenii Dh1 and 26
Dh14 hydrolysates in which both antihypertensive sequences represented 27
approximately 6 (CSH Dh1) and 10% (CSH Dh14) of total peptide content. In 28
addition, a complete analysis of selected CSHs by HPLC-MS/MS allowed the 29
identification of 35 (Dh1) and 46 (Dh14) additional peptides, which could also 30
contribute to the observed in vitro ACE inhibitory potency of both hydrolysates 31
(Dh1, IC50 = 13.6 ± 1.8 µg/mL; Dh14, IC50 = 17.5 ± 2.1 µg/mL) and might confer 32
them multifunctional properties. Finally casein zymography revealed the 33
presence of at least one extracellular protease with a molecular mass of about 34
50 kDa. In conclusion, the present study contributes to a better insight into 35
bioactive compounds produced by dairy yeasts and shows the feasibility of D. 36
hansenii strains to produce antihypertensive casein-derived peptides.37
38
Keywords: Dairy yeasts, Debaryomyces hansenii, Kluyveromyces lactis, 39
Kluyveromyces marxianus, casein-derived antihypertensive peptides.40
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Abbreviations 43
ACE: angiotensin I-converting enzyme; CSH: casein hydrolysate; GRAS: 44
generally recognized as safe; LAB: lactic acid bacteria; RP-HPLC-MS/MS: 45
reversed phase-high performance liquid chromatography tandem mass 46
spectrometry; RP-HPLC-UV-MS: reversed-phase high performance liquid 47
chromatography-UV and mass spectrometry; SHR: spontaneously hypertensive 48
rat.49
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1. Introduction 51
Casein is an excellent substrate to produce peptides with angiotensin I 52
converting enzyme (ACE)-inhibitory and antihypertensive effects (Otte, Shalaby, 53
Zakora, Pripp, & El-Shabrawy 2007; Martínez-Maqueda, Miralles, Recio, & 54
Hernández-Ledesma, 2012). Basically, processing of milk proteins with food 55
grade proteolytic preparations or fermentation of milk with lactic acid bacteria 56
(LAB) proteolytic starters have been employed to release antihypertensive57
peptides. Both approaches have conducted to the development of commercial 58
products based on milk proteins with antihypertensive effects in humans. In fact, 59
one of the most popular functional foods contain the casein-derived ACE-60
inhibitory tripeptides VPP and IPP, which can be obtained by means of either 61
milk fermentation (Nakamura, Yamamoto, Sakai & Takano, 1995) or enzymatic 62
hydrolysis using microbial proteases (Mizuno, Nishimura, Matsuura, Gotou & 63
Yamamoto, 2004).64
We have previously identified casein-derived sequences with 65
antihypertensive activity using both methods. Two novel peptides of sequences 66
RYLGY and AYFYPEL were identified from a peptic casein hydrolysate67
(Contreras, Carrón, Montero, Ramos, & Recio, 2009.). Both exerted in vitro68
inhibitory effects on ACE activity (IC50 values of 0.71 and 6.58 µM, respectively) 69
and effectively decreased systolic blood pressure after oral administration to 70
spontaneously hypertensive rats (SHRs) at 5 mg/kg of body weight. With 71
respect to the fermentation strategy, the antihypertensive sequence LHLPLP 72
was identified as one of the major peptides responsible for the ACE-inhibitory 73
and antihypertensive effects of fermented milk produced by Enterococcus 74
faecalis (Muguerza et al., 2006; Quirós et al., 2007). This sequence showed an 75
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IC50 value of 5.5 ± 0.4 µM against ACE activity and exhibited potent 76
antihypertensive effect at a dose of 2 mg/kg (Quirós et al., 2007). Further 77
characterization suggested the pentapeptide HLPLP as the minimum active 78
form responsible for the antihypertensive effect of LHLPLP (Quirós, Dávalos, 79
Lasunción, Ramos, & Recio, 2008.). Since the pathogenic potential of some 80
Enterococcus strains (Franz, Holzapfel, & Stiles, 1999) may hamper their use in 81
the food industry, production of HLPLP by enzymatic hydrolysis with food-grade 82
enzymes was also optimized (Quirós, Hernández-Ledesma, Ramos, Martín-83
Álvarez, & Recio, 2012).84
The impact of proteolytic yeast strains on the release of ACE-inhibitory 85
peptides in fermented milk has been recently described (Chaves-López, Tofalo, 86
Serio, Paparella, Sacchetti, & Suzzi, G, 2012; Chaves-López et al., 2014). We 87
have shown the ability of some proteolytic dairy yeast strains belonging to 88
Debaryomyces hansenii, Kluyveromyces lactis and Kluyveromyces marxianus89
species to generate casein-derived antihypertensive hydrolysates (García-90
Tejedor, Padilla, Salom, Belloch, & Manzanares, 2013). With the aim of further 91
characterize these non-conventional dairy yeasts as feasible GRAS (Generally 92
Recognized As Safe) microorganisms for the production of antihypertensive 93
peptides, here we screen up to thirty-three of these strains on the basis of their 94
ability to release previously identified casein-derived antihypertensive 95
sequences (RYLGY, AYFYPEL, LHLPLP, HLPLP, VPP and IPP) obtained 96
either by enzymatic hydrolysis or bacterial fermentation. In addition, the 97
presence of extracellular caseinolytic activity in selected strains is evaluated. 98
Finally, quantification of the aforementioned sequences and identification of 99
new main casein-derived peptides in the selected yeast casein hydrolysates are100
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carried out, and their potential bioactivities in terms of ACE inhibition and other 101
functional effects are discussed.102
103
2. Materials and Methods 104
2.1. Materials 105
Casein (Promilk 85) was obtained from Ingredia (Arrax Cedex, France). 106
ACE from porcine kidney, bicinchoninic acid protein assay kit, Hammarsten 107
casein and Triton X-100 were purchased from Sigma (St. Louis, MO, USA).108
Glucose was obtained from Panreac (Barcelona, Spain), bacteriological 109
peptone was purchased from Cultimed (Barcelona, Spain) and yeast extract 110
and agar were acquired from Pronadisa (Madrid, Spain). The fluorogenic 111
substrate o-aminobenzoyl-Gly-p-nitro-Phe-Pro was provided by Bachem 112
Feinchemikalien (Bubendorf, Switzerland). Coomassie Brilliant Blue G-250,113
30% acrylamide/bis solution 29:1 and Precision Plus Protein Dual Color 114
standards were obtained from Bio-Rad Laboratories (Hercules, CA, USA).115
116
2.2. Yeast strains and growth conditions 117
Thirty-three yeast strains belonging to D. hansenii (Dh1-Dh23), K. lactis118
(Kl1-Kl8) and K. marxianus (Km1-Km2) species isolated from artisanal ewes’ 119
and goats’ milk cheeses (Padilla, Manzanares & Belloch, 2014) were used in 120
this study. Yeast strains were maintained on GPYA medium (2% glucose, 0.5% 121
peptone, 0.5% yeast extract and 2% agar, pH 5.5).122
123
2.3. Preparation of casein hydrolysates 124
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Stock solution of casein was sterilized by autoclaving at 121°C, 15 min. 125
Casein medium (2% casein, 2% glucose) was inoculated with 106 cells/ml from 126
pre-cultured strains on GPY (GPYA without agar) and incubated at 28°C and 127
100 rpm in an orbital shaker for 6 days. At the end of the incubation period128
yeast cells were sedimented by centrifugation (3220 x g, 10 min), and the 129
supernatants ultrafiltered using Amicon Ultra 10K centrifugal filter devices 130
(Millipore Corporation, Billerica, MA, USA). Supernatant ultrafiltrates enriched in131
peptides of molecular weight lower than 10 kDa were considered as casein 132
hydrolysates (CSHs). Supernatant concentrates (> 10 kDa) were used for 133
zymography experiments as specified further.134
Protein concentration was estimated by the bicinchoninic acid method 135
using bovine serum albumin as standard (Ruiz-Giménez et al., 2012).136
137
2.4. In vitro assay of ACE-inhibitory activity 138
In vitro ACE-inhibitory activity of CSHs was measured using the 139
fluorescent method described by Sentandreu & Toldrá (2006) based on the 140
hydrolysis of the internally quenched fluorescent substrate o-aminobenzoyl-Gly-141
p-nitro-Phe-Pro by the action of ACE.142
The IC50 value of CSHs was defined as the protein concentration 143
required to inhibit 50% of the ACE activity, and the value for each experiment 144
was estimated by non-linear regression of the experimental data to a four-145
parameter logistic curve using the software package SigmaPlot v 10.0 (SPSS 146
Inc., Chicago, IL, USA).147
148
2.5. Casein zymography 149
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Zymography was performed according to Folio, Ritt, Alexandre, & 150
Remize (2008) with minor modifications. Briefly, samples (casein supernatant 151
concentrates) in loading buffer without β-mercaptoethanol were loaded onto a 152
10% (w/v) SDS/PAGE gel (Laemmli, 1970) co-polymerized with 0.12% (w/v) 153
Hammarsten casein. After electrophoresis and brief washing in ultrapure water, 154
the gel was washed for 2 h on a rotary shaker with 2.5% (v/v) Triton X-100. 155
Afterwards the gel was washed twice with reaction buffer (50 mM citrate 156
phosphate buffer, pH 6) and then incubated overnight in reaction buffer at room 157
temperature. The gel was stained with 0.1% (w/v) Coomassie Brilliant Blue G-158
250 for 1 h and then de-stained. Protease activity bands were visualized as 159
white bands on a dark blue background.160
161
2.6. Synthesis and quantification of peptides HLPLP and LHLPLP 162
The peptides HLPLP f(134-138) and LHLPLP f(133-138) from β-casein, 163
were synthesized in-house using the fluorenyl-methoxy-carbonyl chloride 164
(Fmoc) solid-phase method with a 431A peptide synthesizer (Applied 165
Biosystems Inc. Überlingen, Germany). Peptide purity was calculated by 166
reversed phase high performance liquid chromatography-UV and mass 167
spectrometry (RP-HPLC-UV-MS).168
Six-point calibration curves of the pure peptides HLPLP and LHLPLP 169
(from 1.95 to 62.5 μg/mL) were prepared in Milli-Q deionized water. Duplicate 170
injections were done for each point on the calibration curve. The quantification 171
of the peptides in each CSH was performed by the extraction of their 172
characteristic ions.173
174
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2.7. Peptide sequencing by reversed phase-high-performance liquid 175
chromatography tandem mass spectrometry (RP-HPLC-MS/MS).176
The analyses of CSHs by RP-HPLC-MS/MS were performed on an 177
Agilent HPLC (Agilent Technologies, Waldbronn, Germany) system followed by 178
on-line MS/MS analysis on a quadrupole ion trap instrument (Esquire 3000, 179
Bruker Daltonik GmbH, Bremen, Germany) as previously described (Sánchez-180
Rivera, Diezhandino, Gómez-Ruiz, Fresno, Miralles, & Recio, 2014).181
Chromatographic separations were performed with a Mediterranea Sea18 150 182
mm × 2.1 mm column (Teknokroma, Barcelona, Spain). The flow rate was 0.2 183
mL/min and the injection volume 50 L. Peptides were eluted with a linear 184
gradient from 0% to 45% of solvent B (acetonitrile:formic acid 0.1%) and 55% 185
solvent A (water:formic acid 0.1%) in 120 min. The target mass was set at 186
mass-to-charge ratio (m/z) 750, and the mass acquisition ranged from 200 to 187
2000 m/z.188
189
2.8. Statistical data analysis 190
IC50 values of CSHs were compared using Student’s t-test. Differences 191
with P-values < 0.05 were considered significant. Data statistical analysis was 192
performed using the GraphPad Prism 4 software (GraphPad Software Inc, La 193
Jolla, CA, USA).194
195
3. Results and discussion 196
Non-Saccharomyces yeasts have been utilized as industrial organisms 197
for a variety of biotechnological roles since numerous and diverse biological 198
activities make them promising candidates for a wide range of applications not 199
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limited to the food sector. They are increasingly being used as hosts for 200
expression of proteins, biocatalysts and multienzyme pathways for the 201
synthesis of fine chemicals and small molecular weight compounds of medicinal 202
and nutritional importance (Jonhson, 2013).203
In the present study, 33 CSHs generated by D. hansenii (CSH Dh1-204
Dh23) K. lactis (CSH Kl1-Kl8) and K. marxianus (CSH Km1-Km2) strains 205
isolated from artisanal cheeses (Padilla et al., 2014) were analysed by HPLC-206
MS/MS to search for the previously identified antihypertensive sequences207
RYLGY, AYFYPEL, LHLPLP, HLPLP, VPP and/or IPP. Peptides RYLGY, 208
AYFYPEL, VPP and IPP were not identified in any of the CSHs. However, 209
peptide HLPLP and its precursor sequence LHLPLP were released from casein 210
after growth of D. hansenii strains Dh1 and Dh14. Figure 1 shows the UV 211
chromatogram and the extracted ions corresponding to both peptides.212
Quantification of HLPLP and LHLPLP in CSH Dh1 and Dh14 was carried 213
out using linear regressions obtained by HPLC-MS/MS. As shown in Table 1,214
highest total content was obtained in CSH Dh14. However both hydrolysates 215
contained similar quantities of the pentapeptide. These antihypertensive 216
peptides represented approximately 6 and 10% of total peptide content in Dh1 217
and Dh14 hydrolysates, respectively. No significant differences were found 218
between the ACE inhibitory potencies of both D. hansenii CSHs, which showed 219
IC50 values of 13.6 ± 1.8 µg/mL (Dh1) and 17.5 ± 2.1 µg/mL (Dh14). ACE 220
inhibition was slightly higher than the previously reported values of milk 221
fermented by E. faecalis (34-59 µg/mL; Muguerza et al., 2006) but lower than 222
that showed by a pepsin casein hydrolysate (5.68 µg/mL; Contreras et al., 223
2009). 224
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During milk fermentation, proteolysis by LAB has been studied in detail. 225
The key enzyme in this process is a cell-envelope proteinase involved in the 226
first step of casein degradation (Savijoki, Ingmer, & Varmanen, 2006). By 227
contrast, although yeast caseinolytic activity is well documented few reports 228
deal with the characterization of the extracellular proteolytic system. With 229
regards to D. hansenii, Kumura, Takagaki, Sone, Tsukahara, Tanaka, & 230
Shimazaki (2002) reported that a cell-wall associated protease acted on β-231
casein whereas S-casein degradation was attributed to an intracellular 232
protease released by cell lysis. However, extracellular proteolytic activity on 233
both S- and β-casein for D. hansenii strains isolated from cheese has been 234
described (Gardini et al., 2006). Here we conducted a casein zymography to 235
detect extracellular proteases in the supernatants of the two selected D. 236
hansenii strains. On casein substrate, extracellular proteolytic activities were237
detected (Figure 2). Analysis of Dh14 supernatant revealed the presence of one 238
hydrolysis band which corresponded to a molecular mass of about 50 kDa. The 239
same band was observed in Dh1 supernatant, in which a second band of 240
slightly higher molecular mass was also detected. Band intensities for both 241
supernatants were not related to the amount of total protein loaded (Dh1, 4.8 242
µg; Dh14, 4.4 µg). Although increasing amounts of Dh14 total protein were 243
loaded onto SDS/PAGE gels for protease detection no other clear activity bands 244
were observed (data not shown). These results might suggest a different 245
proteolytic profile for both strains in the conditions tested. Future work should 246
include purification of the extracellular D. hansenii enzymes and determination 247
of its biochemical properties.248
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Over the last two decades, a large number of casein-derived peptides 249
obtained by fermentation and enzymatic hydrolysis with ACE-inhibitory potency 250
and proven antihypertensive effects in SHRs have been identified (Martínez-251
Maqueda et al., 2012). Although LHLPLP and HLPLP might contribute to the 252
inhibitory potency of D. hansenii CSHs, other sequences generated from casein 253
hydrolysis might also be responsible for the observed inhibitory effects. This 254
prompted us to carry out a complete analysis of CSH Dh1 and Dh14 by HPLC-255
MS/MS, which allowed the identification of 35 and 46 additional peptides (Table 256
2 and 3), respectively. The most abundant peptides in each hydrolysate are 257
given in bold. As can be seen in Table 2, most of the peptides present in CSH 258
Dh1, derived from hydrolysis of αS1-CN (15 fragments) and β-CN (14 fragments) 259
whereas only 6 and 2 peptides corresponded to αS2-CN and ĸ-CN fragments, 260
respectively. By contrast, in CSH Dh14 most of the peptides (37 fragments) 261
derived from β-CN. In addition 9 fragments from αS1-CN and 2 from ĸ-CN were 262
also identified, while none of the fragments derived from αS2-CN. Finally, only 263
11 of the peptides identified, including the two antihypertensive sequences 264
LHLPLP and HLPLP, were common for both D. hansenii strains, which 265
indicates strain-specific proteolysis in accordance with the results obtained in 266
the zymogram and also as described for the Streptococcus thermophilus cell 267
envelope proteinase (Miclo et al., 2012).268
Sequences LHLPLP and HLPLP were also included in several longer 269
fragments identified in CSH Dh14, such as LHLPLPL, HLPLPL and 270
LHLPLPLLQS. The heptapeptide LHLPLPL, with an IC50 value of 425 ± 44 µM271
against ACE, was also identified in E. faecalis fermented milk (Quirós et al., 272
2007). Another peptide (β-CN f(58-76), LVYPFPGPIPNSLPQNIPP; IC50 = 5.2 ± 273
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0.3 µM) identified in E. faecalis fermented milk caused also significant decrease 274
of the systolic blood pressure in SHRs (Quirós et al., 2007). Part of this 275
sequence (VYPFP) was also identified in both D. hansenii CSHs. On the other 276
hand, although neither VPP nor IPP were found in D. hansenii CSHs, 277
sequences containing the latter at the N-terminal end were identified (IPPL, 278
IPPLTQ, IPPLTQT and IPPLTQTP). Whether these newly identified sequences 279
could also contribute to the ACE-inhibitory activity of CSH Dh1 and Dh14280
deserves further characterization studies. Moreover, the role of gastrointestinal 281
digestion to generate active fragments from longer sequences should also be 282
taken into account, although degradation of active fragments can also occur.283
More than 60% of the identified sequences have at least one Pro 284
residue. Particularly, Pro in the C-terminal and antepenultimate position has 285
been recognised as one of the most favourable residues for peptide binding to 286
the active site of ACE (Rohrbach, Willians, & Rolstad, 1981). Interestingly, in 287
addition to the antihypertensive sequences LHLPLP and HLPLP, peptides 288
VAPFP, DIPNP, VYPFP, FSDIPNP and GPVRPFP with a Pro residue in both 289
positions might be promising candidates to inhibit ACE activity. Finally, some 290
other sequences identified in CSH Dh1 and Dh14 were previously characterized 291
as ACE-inhibitory and antioxidant peptides (sequence YQEP in Dh1; Silva, 292
Pihlanto, & Malcata, 2006) or having lipoxygenase inhibitory properties 293
(VLPVPQK in Dh1; Rival, Fornaroli, Boeriu, & Wichers, 2001). Also some 294
sequences identified here share structure homology with fragments able to 295
inhibit prolyl-peptidases of human colon cells (FVAPFPE, VAPPFP and 296
VAPFPE in Dh1; Juillerat-Jeanneret, Robert, & Juillerat, 2011) or having 297
immune-modulating and ACE-inhibitory properties (GPVRGPFPI and 298
14 
GPVRGPFP in Dh14; Hayes, Stanton, FitzGerald, & Ross, 2007; Hernández-299
Ledesma, Amigo, Ramos, & Recio, 2004). The multifunctional properties and 300
the resulting health benefits of dairy protein hydrolysates have been pointed out 301
by several studies (reviewed in Hernández-Ledesma, García-Nebot, 302
Fernández-Tomé, Amigo, & Recio, 2014). To what extent D. hansenii CSHs303
might exert different functional effects requires further research.304
D. hansenii is a highly heterogeneous, and thus versatile, species which 305
represents an attractive target for fundamental and applied biotechnological 306
research (Johnson, 2013; Hatoum et al., 2013). Our results point to dairy D. 307
hansenii strains Dh1 and Dh14 as feasible GRAS microorganisms with strain-308
specific caseinolytic systems for the production of the antihypertensive 309
sequences HLPLPL and HLPLP. These two peptides could at least in part be 310
responsible for the ACE-inhibitory properties of both D. hansenii CSHs, 311
although data reported here suggest that other potential bioactive sequences 312
are also produced. D. hansenii, one of the predominant yeast species in all type 313
of cheeses, plays important roles in cheese making and further investigation is 314
needed to exploit its biotechnological potential.315
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Table 1. Content of peptides LHLPLP and HLPLP in casein hydrolysates (CSH) 436
Dh1 and Dh14.437
CSH LHLPLP
(µg/mg)
HLPLP
(µg/mg)
Total
(µg/mg)
Dh1 15.6 43.5 59.1
Dh14 52.7 46.4 99.1
438
439
21 
Table 2. Identification of peptides contained in D. hansenii casein hydrolysate 
(CSH) Dh1.
Ion for 
MS/MS (m/z)a
Observed 
massb
Theoretical 
mass
Protein fragment Identified 
sequencec
806.388 805.372 805.401 αS1-CN f(24-30) FVAPFPE 
530.179 529.172 529.29 αS1-CN f(25-29) VAPFP 
659.312 658.304 658.333 αS1-CN f(25-30) VAPFPE 
608.373 607.366 607.333 αS1-CN f(32-36) FGKEK 
618.394 617.387 617.302 αS1-CN f(35-39) EKVNE 
632.362 631.354 631.318 αS1-CN f(81-85) IQKED 
502.15 501.143 501.28 αS1-CN f(95-98) LEQL 
468.196 467.189 467.249 αS1-CN f(127-130) IHAQ 
602.321 601.313 601.307 αS1-CN f(138-142) VNQEL 
680.309 679.302 679.297 αS1-CN f(159-164) YPSGAW 
517.184 516.177 516.233 αS1-CN f(160-164) PSGAW 
777.435 776.428 776.407 αS1-CN f(167-173) VPLGTQY 
581.257 580.25 580.286 αS1-CN f(169-173) LGTQY 
555.344 554.337 554.27 αS1-CN f(181-185) DIPNP 
519.164 518.156 518.234 αS1-CN f(186-190) IGSEN 
602.321 601.313 601.253 αS2-CN f(4-8) MEHVS 
1000.532 999.525 999.539 αS2-CN f(100-108) YQGPIVLNP 
837.459 836.452 836.476 αS2-CN f(101-108) QGPIVLNP 
698.394 697.386 697.401 αS2-CN f(116-122) AVPITPT 
528.248 527.24 527.296 αS2-CN f(118-122) PITPT 
720.417 719.409 719.422 αS2-CN f(198-203) TKVIPY 
628.27 627.263 627.323 β-CN f(6-11) LNVPGE 
748.265 747.258 747.304 β-CN f(38-43) QQQTED 
622.309 621.302 621.316 β-CN f(59-63) VYPFP 
439.026 438.018 438.284 β-CN f(74-77) IPPL 
668.38 667.373 667.39 β-CN f(74-79) IPPLTQ 
732.347 731.34 731.385 β-CN f(113-118) KYPVEP 
690.282 689.275 689.323 β-CN f(127-132) LTDVEN 
577.164 576.157 576.239 β-CN f(128-132) TDVEN 
689.449 688.442 688.427 β-CN f(133-138) LHLPLP 
576.304 575.297 575.343 β-CN f(134-138) HLPLP
649.265 648.258 648.28 β-CN f(144-148) MHQPH 
805.351 804.343 804.384 β-CN f(155-161) VMFPPQS 
780.457 779.45 779.491 β-CN f(170-176) VLPVPQK 
536.148 535.14 535.228 β-CN f(193-196) YQEP 
633.35 632.343 632.353 k-CN f(26-30) IPIQY 
663.318 662.311 662.339 k-CN f(43-47) YQQKP 
aCharge of precursor ion: 1 440
bCalculated monoisotopic mass. 441
cMain peptides are labeled in bold. 442
Casein: CN 443
444
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Table 3. Identification of peptides contained in D. hansenii casein hydrolysate 
(CSH) Dh14.
Ion for MS/MS 
(m/z)a
Observed 
massb
Theoretical 
mass Protein fragment
Identified 
sequencec
805.399 805.378 805.401 αS1-CN f(24-30) FVAPFPE 
676.407 675.400 675.359 αS1-CN f(29-34) PEVFGK 
707.446 706.439 706.401 αS1-CN f(31-36) VFGKEK 
763.321 762.322 762.358 αS1-CN f(54-59) MEDIKQ 
732.394 631.328 631.318 αS1-CN f(55-59) EDIKQ 
903.472 902.465 902.453 αS1-CN f(135-142) MIGVNQEL 
517.171 516.164 516.233 αS1-CN f(160-164) PSGAW 
789.371 788.634 788.370 αS1-CN f(179-185) FSDIPNP 
730.385 729.314 729.329 αS1-CN f(184-190) NPIGSEN 
675.257 674.322 674.324 β-CN f(1-5) RELEE 
649.284 627.306 627.323 β-CN f(6-11) LNVPGE 
633.295 632.288 632.277 β-CN f(38-42) QQQTE 
748.284 747.277 747.304 β-CN f(38-43) QQQTED 
875.371 876.305 876.346 β-CN f(38-44) QQQTEDE 
632.355 631.335 631.318 β-CN f(44-48) ELQDK 
681.303 680.296 680.313 β-CN f(52-57) FAQTQS 
622.309 621.302 621.316 β-CN f(59-63) VYPFP 
668.416 667.409 667.390 β-CN f(74-79) IPPLTQ 
769.342 768.386 768.438 β-CN f(74-80) IPPLTQT 
866.472 865.465 865.491 β-CN f(74-81) IPPLTQTP 
753.385 752.378 752.407 β-CN f(75-81) PPLTQTP 
689.313 688.395 688.412 β-CN f(95-100) VSKVKE 
760.456 759.449 759.449 β-CN f(95-101) VSKVKEA 
577.327 576.267 576.294 β-CN f(98-102) VKEAM 
651.384 650.376 650.343 β-CN f(111-115) FPKYP 
732.274 731.364 731.385 β-CN f(113-118) KYPVEP 
611.329 610.267 610.260 β-CN f(119-123) FTESQ 
698.269 697.262 697.292 β-CN f(119-124) FTESQS 
904.446 903.439 903.455 β-CN f(125-132) LTLTDVEN 
689.313 688.392 688.427 β-CN f(133-138) LHLPLP 
802.505 801.498 801.511 β-CN f(133-139) LHLPLPL 
1130.667 1129.660 1129.686 β-CN f(133-142) LHLPLPLLQS 
576.334 575.327 575.343 β-CN f(134-138) HLPLP 
793.521 792.514 792.511 β-CN f(135-141) LPLPLLQ 
880.515 879.508 879.543 β-CN f(135-142) LPLPLLQS 
670.420 669.413 669.406 β-CN f(137-142) LPLLQS 
533.184 532.177 532.265 β-CN f(140-143) LQSW 
649.329 648.277 648.280 β-CN f(144-148) MHQPH 
805.402 804.348 804.384 β-CN f(155-161) VMFPPQS 
649.327 648.320 648.344 β-CN f(164-169) SLSQSK 
543.270 542.262 542.343 β-CN f(168-172) SKVLP 
559.253 558.246 558.284 β-CN f(185-189) MPIQA 
762.385 761.378 761.396 β-CN f(191-196) LLYQEP 
649.318 648.310 648.312 β-CN f(192-196) LYQEP 
826.445 825.438 825.450 β-CN f(199-206) GPVRGPFP 
939.500 938.493 938.534 β-CN f(199-207) GPVRGPFPI 
658.370 657.363 657.370 k-CN f(119-124) IPTINT 
757.362 756.355 756.365 k-CN f(155-161) SPPEINT 
aCharge of precursor ion: 1 445
bCalculated monoisotopic mass. 446
cMain peptides are labeled in bold. 447
CN: casein 448
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Figure captions 449
450
Figure 1. UV chromatogram of the casein hydrolysate Dh1 (A) and Dh14 (B). 451
Extracted Ion chromatogram (EIC) of the peptides LHLPLP and HLPLP in Dh1 452
(C) and Dh14 (D). Fragmentation pattern of LHLPLP (E) and of HLPLP (F), with 453
mass-to-charge ratios (m/z) of 689.5 and 576.3, respectively.454
455
Figure 2. Casein zymography of D. hansenii Dh1 and Dh14 extracellular 456
proteolytic activities. Lane M, molecular weight markers (Precision Plus Protein 457
Dual Color standards, Bio-Rad); lane 1, Dh1 culture supernatant concentrate 458
(4.8 µg); lane 2, Dh14 culture supernatant concentrate (4.4 µg).459
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